PARP Inhibitors for Early, BRCA-Mutant Breast Cancer
PARP inhibitors have emerged as important new therapies for breast cancer patients who have an inherited BRCA mutation. Use of these agents in the neoadjuvant…
Browsing Tag
BRCAMutant
PARP Inhibitor Staves Off Recurrence in Early BRCA-Mutant Breast Cancer
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival in patients with early, high-risk HER2-negative breast…
Clinical Challenge: BRCA-Mutant Triple-Negative Breast Cancer
The majority of breast cancers are "sporadic," developing in patients with no associated hereditary mutations. On the other hand, hereditary cancer susceptibility gene mutations, the…
Olaparib Wins in Early BRCA-Mutant Breast Cancer
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in patients with early, high-risk HER2-negative breast cancer and…